The Relative Strength (RS) Rating for Ligand Pharmaceuticals stock entered a new percentile Thursday, with an increase from 80 to 84.
Looking For The Best Stocks To Buy And Watch? Start Here
This unique rating tracks market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the trailing 52 weeks matches up against other publicly traded companies.
Decades of market research shows that the best stocks often have an RS Rating of over 80 as they launch their biggest price moves.
Is Ligand Pharmaceuticals Stock A Buy?
Ligand Pharmaceuticals stock is still inside a buying range after climbing above a 129.90 entry in a consolidation. Once a stock moves 5% or higher beyond the original entry, it's considered out of buy range.
The Florida-based biotech company showed -65% EPS growth in the latest quarterly report. Revenue gains came in at 46%. The next quarterly numbers are expected on or around Aug. 11.
Is Ligand Pharmaceuticals stock earns the No. 12 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
